Validity of the Turkish Situational Vertigo Questionnaire

March 9, 2026 updated by: Ebru Sever, Istanbul Medipol University Hospital

Turkish Adaptation of the Situational Vertigo Questionnaire: Validity and Reliability Study

This study was planned to examine the validity and reliability of the Turkish version of the Situational Vertigo Questionnaire (SVQ), which is used to evaluate dizziness symptoms frequently seen in vestibular pathologies and triggered by visual or environmental stimuli. The research is designed as a methodological scale adaptation and psychometric evaluation study. The study plans to include individuals aged 18 and over who can read and understand Turkish and have complaints of situational dizziness. The Turkish adaptation process of the SVQ will be carried out using the back-and-forth translation method; a pilot application will be conducted after ensuring linguistic and cultural equivalence. For the psychometric evaluation, the sample size is planned to be at least 10 times the number of items, and participants will be asked to complete the SVQ, as well as the Dizziness Handicap Inventory (DHI), Vertigo Symptom Scale (VSS), and Visual Analog Scale (VAS). To evaluate test-retest reliability, a subgroup of participants will be re-administered the SVQ after 7 days. No invasive procedures will be performed on participants during the research; only survey forms will be used. Written informed consent will be obtained from all participants, and data will be coded and analyzed in accordance with confidentiality principles. It is expected that the findings of this study will contribute to the literature by establishing a valid and reliable measurement tool in Turkish for the evaluation of situational dizziness symptoms and will support clinical evaluation processes.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Turkey (Türkiye)
    • Güneşli
      • Bağcılar, Güneşli, Turkey (Türkiye), 34200
        • Recruiting
        • Güneşli Erdem Hastanesi
        • Contact:
          • Güneşli Erdem hastane
          • Phone Number: 08502220494

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Frequent complaints of dizziness and imbalance in vestibular pathologies are significant clinical problems that negatively affect individuals' daily life activities, social participation, and quality of life. In particular, valid and reliable measurement tools reflecting the individual's subjective experience are needed in the evaluation of situational dizziness symptoms triggered by visual or environmental stimuli. In this context, the Situational Vertigo Questionnaire (SVQ), widely used in the international literature, stands out as an important tool in the evaluation of dizziness symptoms associated with situational and visual stimuli.

Description

Inclusion Criteria:

  • Presence of dizziness triggered by visual or environmental stimuli
  • Able to read and write Turkish
  • Voluntary agreement to participate in the study
  • Having the mental capacity to give informed consent (Mini Mental State Scale score ≥ 24)

Exclusion Criteria:

  • Individuals with severe cognitive impairment or communication difficulties
  • Acute neurological disease (stroke, acute MS relapse, etc.)
  • Having undergone vestibular surgery within the last 3 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Vestibular Patients
The target population of this study consists of individuals aged 18 years and older who can read and understand Turkish and experience dizziness triggered by visual or environmental stimuli. Written informed consent will be obtained from all participants. Sociodemographic and clinical characteristics, including age, sex, occupation, smoking and alcohol use, comorbidities, medical history, medications, daily activity level, onset and type of the condition, fall history, and sensitivity to heights, darkness, and crowded environments, will be recorded using a researcher-designed form. Based on the "item number × 10" rule, at least 190 participants will be included for the 19-item Situational Vertigo Questionnaire (SVQ). Participants will complete the SVQ, Dizziness Handicap Inventory (DHI), and Vertigo Symptom Scale (VSS), and rate satisfaction using a Visual Analog Scale. Test-retest reliability will be assessed in at least 20% of participants after 7-14 days.
Other: validity and reliability
The Turkish adaptation of the Situational Vertigo Questionnaire (SVQ) will follow internationally accepted cross-cultural adaptation guidelines using a forward-backward translation method. Two independent bilingual translators will translate the original English version into Turkish, producing two versions that will be compared and synthesized into a preliminary Turkish form. This version will then be back-translated into English by two native English speakers blinded to the original scale. A committee of translators and experts will review all versions to ensure conceptual and linguistic equivalence and create a pre-final Turkish version. The pre-final version will be pilot tested with 20 participants to assess clarity and comprehension. Items reported as unclear will be revised. Finally, the scale will be administered to a larger sample for psychometric evaluation of validity and reliability.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Situational Vertigo Questionnaire (SVQ)
Time Frame: Baseline and 7-14 days follow-up
The Situational Vertigo Questionnaire (SVQ) is a 19-item self-report scale designed to assess visual vertigo associated with increased visual dependence and insufficient vestibular compensation. Visual vertigo refers to dizziness triggered or worsened in visually complex or disorienting environments such as supermarkets, driving, or moving visual scenes. The condition is thought to arise from difficulties resolving conflicts between visual, vestibular, and proprioceptive inputs. The SVQ asks individuals to rate the severity of dizziness in situations involving visual motion or visual-vestibular conflict. Each item is scored from 0 (none) to 4 (severe), and participants may select "never experienced" if applicable. The total score is calculated based on the average item score, adjusted for items marked as not experienced, with higher scores indicating more severe symptoms.
Baseline and 7-14 days follow-up

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Dizziness Handicap Inventory (DHI)
Time Frame: Baseline and 7-14 days follow-up
The scale is used to evaluate the physical, emotional, and functional effects of vestibular disorders. Items 1, 4, 8, 11, 13, 17, and 25 assess physical disability; items 2, 9, 10, 15, 18, 20, 21, 22, and 23 assess emotional disability; and items 3, 5, 6, 7, 12, 14, 16, 19, and 24 assess functional disability. Each item is scored as "yes" (4 points), "no" (0 points), or "sometimes" (2 points). Cut-off values of 28 points for physical disability and 36 points for functional and emotional disability are used. Higher scores indicate more severe dizziness-related impairment.
Baseline and 7-14 days follow-up
Vertigo Symptom Scale (VSS)
Time Frame: Baseline and 7-14 days follow-up
This questionnaire is designed to assess symptoms accompanying dizziness or perceived imbalance, their frequency, the individual's general mood and anxiety level, and the impact of these symptoms on quality of life. Participants rate each symptom according to how often it occurs using a scale from 0 to 4 (0 = never, 1 = very rarely, 2 = sometimes, 3 = often [about once a week], 4 = very often [most days]). The Turkish validity and reliability of the scale was established by Yanık and colleagues.
Baseline and 7-14 days follow-up

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Participant Satisfaction/Visual Analog Scale (VAS)
Time Frame: Baseline and 7-14 days follow-up
Participant satisfaction and enjoyment will be assessed using a 10-cm Visual Analog Scale (VAS). The scale consists of a 10 cm (100 mm) horizontal or vertical line with endpoints representing opposite extremes. In this study, one end indicates "very good satisfaction" and the other indicates "very poor satisfaction (0)." Participants mark the point that best represents their perception. Although commonly used to measure pain intensity, the VAS is also widely applied to evaluate various subjective outcomes. In this study, it will be used to assess participants' level of satisfaction.
Baseline and 7-14 days follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Istanbul Medipol University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
February 16, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 2, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 20, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 9, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 9, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 13, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 13, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 9, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • SVQ Validity and Reliability

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings